Eupraxia Pharmaceuticals (EPRX) Revenue (2023 - 2025)
Eupraxia Pharmaceuticals' (EPRX) quarterly Revenue came in at $359739.0 in Q1 2025, down 58.3% year-on-year from $862683.0 in Q1 2024, and down 58.3% on a QoQ basis from $862683.0 in Q1 2024.
Eupraxia Pharmaceuticals (EPRX) Revenue (2023 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 3 years of Revenue data on file, last reported at $359739.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Eupraxia Pharmaceuticals | 329.50 Mn | 329.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 359,739.00 |
| Mar 31, 2024 | 862,683.00 |
| Mar 31, 2023 | -128,152.00 |